The future of public health is set to become increasingly digital, with technological advancements enabling healthcare players to provide more targeted and effective interventions to patien
In the ever-evolving landscape of the biotechnology sector, the ability to attract investors effectively stands as the decisive factor that separates the success of your pioneering research
In 2017, MSD made the decision to open a $1.32 billion, 220,000 sq ft research facility in the heart of London’s ‘knowledge quarter’ around King’s Cross.
In the ever-evolving landscape of the biotechnology sector, the ability to attract investors effectively stands as the decisive factor that separates the success of your pioneering research
Bayer is backing up its move into the cell therapy category led by subsidiary BlueRock Therapeutics with a $250 million investment in a new manufacturing facility in Berke